Can the Large-Scale Decrement in Repetitive Nerve Stimulation Be Used as an Exclusion Criterion for Amyotrophic Lateral Sclerosis?

Li Shang†, Hong Chu† and Zuneng Lu*

Department of Neurology, Renmin Hospital, Wuhan University, Wuhan, China

Objective: The objectives of this work were to identify the characteristics of repetitive nerve stimulation (RNS) in patients with amyotrophic lateral sclerosis (ALS) and further verify the electrophysiological exclusion criteria of ALS.

Methods: A total of 150 patients with ALS who were admitted to the Department of Neurology of Renmin Hospital of Wuhan University from January 2015 to December 2018 were enrolled. Clinical and electrophysiological data of the enrolled patients were collected. The differences in the amplitudes of the compound muscle action potential (CMAP) between the trapezius muscle (Trap) and the abductor digiti minimi (ADM) in low-frequency RNS were compared. Furthermore, we analyzed the associations between decremental responses and gender, onset age, duration of disease, onset site, Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (ALSFRS-R), disease progression rate, and CMAP amplitude.

Results: A significant decrement (≥20%) in at least one muscle was observed in 11.3% of the ALS patients, while decrements (≥10%) in at least one muscle were observed in 41.3%. The decremental percentage in the trapezius muscle was significantly higher than that in the abductor digiti minimi (P < 0.001). The onset age, duration of disease, onset site, and disease progression rate did not affect decremental responses. The decremental responses in RNS were more significant in ALS patients with low ALSFRS-R scores (P = 0.01). Moreover, there was a positive linear correlation between the CMAP amplitude and the decremental percentage of Trap and ADM in ALS patients.

Conclusions: CMAP decremental responses in RNS were common in ALS patients, suggesting abnormalities of neuromuscular junctions (NMJs). It is worthy of further discussion whether to consider a decrement >20% in RNS as a diagnostic exclusion criterion for ALS.

Keywords: amyotrophic lateral sclerosis, repetitive nerve stimulation, electrophysiological diagnostic criteria, compound muscle action potential, neuromuscular junctions
INTRODUCTION

Amyotrophic lateral sclerosis (ALS), the most quintessential motor neuron disease, affects both upper and lower motor neurons, and leads to progressive muscle atrophy and weakness (1). Mulder et al. (2) originally reported that decremental responses in low-frequency repetitive nerve stimulation (RNS) tests were observed in ALS patients. Subsequently, domestic and foreign studies have confirmed this phenomenon (3–5). The electrophysiological diagnostic criteria of ALS revised by the World Federation of Neurology Research Group on Motor Neuron Diseases pointed out that a significant compound muscle action potential (CMAP) decrement >20% in RNS was a diagnostic exclusion criterion for ALS (6). However, later studies demonstrated that a decrement >20% was observed in ALS patients (4, 7, 8). So far, none of the published studies has indicated the proportion of patients with a decrement of 20% or greater. And the exclusion criteria have not been extensively validated. In addition, the amplitude and incidence of decremental responses and the criteria for the positive decrement were inconsistent among previous research.

In this study, we described the amplitude and incidence of CMAP in low-frequency RNS of ALS patients and explored the correlations between decremental responses and clinical characteristics. We further validated the electrophysiological diagnostic exclusion criteria of ALS, which will enable a better understanding of the disease diagnosis.

METHODS

Patients
A total of 150 patients at the Department of Neurology of Renmin Hospital of Wuhan University were recruited from January 2015 to December 2018. According to the Awaji criteria (9), patients were classified into probable ALS (43 patients) and definite ALS (107 patients). All patients were subjected to rigorous neurological examinations, EMG examinations, blood tests, including serum acetylcholine (ACH) receptor antibodies, cerebrospinal fluid examinations, and imaging studies to exclude important ALS mimics. The exclusion criteria were as follows: (1) patients with a history of poliomyelitis; (2) patients with a positive response to ACH receptor antibodies; (3) patients with spinal cord tumor and with autoimmune disorders; (4) patients with other diseases affecting peripheral nerves, neuromuscular junction (NMJ), or muscles; and (5) patients without complete clinical records.

Method of RNS
All patients underwent routine electromyography performed on a Keypoint Workstation (31A06, Alpine BioMedApS, Denmark), including nerve conduction tests, needle electromyography, and RNS. The detection method followed the national guidelines (10). The surface electrode was stimulated and recorded, and the response to the stimulus was recorded 10 times each time. The accessory nerve was stimulated on the posterior border of the sternocleidomastoid. The ulnar nerve was stimulated on the wrist. The surface recording electrodes were used to record over the belly of the trapezius muscle (Trap) and the abductor digitii minimi (ADM), which respectively represented the proximal muscle and the distal muscle. The reference electrodes were placed on the tendon of the tested muscle. The skin temperature over the examined muscle was maintained at 33°C or above throughout the examination. Filters were set between 20 Hz and 3 kHz.

Study Design

The Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised (ALSFRS-R) was used to calculate the monthly rate of change in ALSFRS-R, which represented the disease progression rate. The greater the value of progression obtained, the faster the disease progressed:

\[
\text{Disease progress rate} = \frac{48 - \text{actual score}}{\text{duration (months)}}
\]

The decremental responses at a frequency of 3 Hz were mainly analyzed. The baseline-to-negative peak amplitudes of the first and fifth CMAPs at the supramaximal intensity (1.25-fold maximal intensity for the M-wave response) were measured. The CMAP decrement in the peak-to-peak amplitude was measured by the decremental percentage of the fifth CMAP as compared to the first CAMP amplitude. Decremental responses of ≥10% were defined as positive. Patients were divided into the positive decrement group and the negative decrement group based on whether the decrement was ≥10%. The data on the lower side of the CMAP amplitude was the standard. The correlations between the decremental responses and ALSFRS-R scores and CMAP amplitude were analyzed.

Statistical Analysis

Statistics calculations were performed on the SPSS 22.0 software. The Kolmogorov–Smirnov test was used to evaluate whether the data were normally distributed. Parameters with a normal distribution were described as the mean ± standard deviation (SD), and those with a non-normal distribution were expressed as the median values (M) and interquartile range (Q). Continuous variables that were normally distributed were compared using Student’s t-test. Mann–Whitney U-tests were implemented to analyze values with a non-normal distribution. The categorical variables were expressed as the number of cases (n) and percentage (%), and the chi-squared test was used for comparison between groups. Correlation analysis was performed using Spearman’s test. \( P < 0.05 \) was considered to be significant.

RESULTS

General Information
There were 85 males and 65 females, with ages from 28 to 80 years (mean age of 56.66 ± 11.29 years), in the included patients. The median duration from symptom onset was 14.34 ± 12.69 months. The ALSFRS-R scores were in the range 24–46, and the median was 40.5. There were 75 cases with upper limb onset and 41 cases with lower limb onset. The rest of the cases were with bulbar onset.
**RNS Results**

The distributions of decremental responses are summarized in Table 1. When the CMAP decrement of $\geq 10\%$ was used as a criterion, the positive decrement in at least one muscle accounted for 41.3% (62/150), most of which were in the proximal muscle (Figure 1). The CMAP decremental percentage ranged from 10 to 29.57%, with an average of 16.63% in patients with a positive decrement.

**Correlation Between Decremental Response and Clinical Features and CMAP Amplitude**

Compared with the patients in the negative decrement group, the patients in the positive decrement group showed lower ALSFRS-R scores and CMAP amplitudes in both proximal and distal muscles (Table 2). There was a positive linear correlation between the CMAP amplitude and the decremental percentage in Trap and ADM of ALS patients ($r = 0.219$, $P = 0.007$; $r = 0.184$, $P = 0.024$, respectively; Figure 2).

**DISCUSSION**

A number of studies have demonstrated that decremental responses were frequently observed in ALS patients. Nevertheless, the positive rate of decremental responses varied due to the diverse sample sizes, muscles, and decremental positive criteria. When the CMAP decrement of $\geq 10\%$ was defined as abnormal, the positive rate of decremental responses was 77% in one study with 48 ALS patients (5), while that in another study including 192 patients in total was only 29% (3). The positive rate of the present study was 41.3%. All of these indicated that decremental positive responses in RNS were common in ALS patients.

In light of the revised ALS diagnostic criteria by the World Federation of Neurology (6), it is noteworthy that a CMAP decrement $>20\%$ was a diagnostic exclusion criterion for ALS. However, our study investigated that

**TABLE 1 | RNS decremental amplitude and frequency in ALS patients.**

| Decremental amplitude | Trap | ADM |
|-----------------------|------|-----|
| $\geq 20\%$           | 16   | 1   |
| $\geq 15\%$           | 15   | 0   |
| $\geq 10\%$           | 31   | 2   |
| $\geq 5\%$            | 27   | 15  |
| $<5\%$                | 61   | 132 |
| Total                 | 150  | 150 |

Trap, trapezius muscle; ADM, abductor digiti minimi; RNS, repetitive nerve stimulation; ALS, amyotrophic lateral sclerosis.

**TABLE 2 | Comparison of positive and negative decrements in ALS patients.**

|                    | RNS+ | RNS− | t/z/χ² | P   |
|--------------------|------|------|--------|-----|
| Sex, n (%)         |      |      |        |     |
| Male               | 32   | 54   | 1.414* | 0.234|
| Female             | 30   | 34   | 0.718  | 0.473|
| Onset age (years)  | 55.12±11.95 | 55.71±10.63 | −0.316| 0.752|
| Disease duration (months) [M/Q] | 12.00 (11.5) | 9.50 (11.5) | −1.695| 0.090|
| ALSFRS-R [M/Q]     | 39.00 (6.0) | 41.00 (5.0) | −2.588| 0.010|
| Disease progression rate [M/Q] | 0.75 (0.7) | 0.70 (1.0) | −0.220| 0.826|
| Onset site, n (%)  |      |      |        |     |
| Bulbar             | 12   | 22   | 0.661* | 0.416|
| Upper limb         | 30   | 45   | 0.833* | 0.316|
| Lower limb         | 20   | 21   | 0.220  | 0.826|
| CMAP amplitude (mV)|      |      |        |     |
| Trap               | 7.53±3.59 | 9.10±3.25 | −2.788* | 0.006|
| ADM                | 7.99±3.74 | 9.94±3.39 | −3.319* | 0.001|

+ Positive decrement; −, Negative decrement.
ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action potential; Trap, trapezius muscle; ADM, abductor digiti minimi.
$\chi^2$-value.
$t$-value.
Bulbar vs. limb onset.
Upper limb onset vs. lower limb onset.

**FIGURE 1 | (A) Decremental frequency in the Trap and ADM of ALS patients. (B) Decremental percentage in the Trap and ADM of ALS patients. Trap, trapezius muscle; ADM, abductor digiti minimi.**
Decremental responses of ALS patients were more pronounced in RNS than do distal muscles, indicating a greater sensitivity of the proximal muscle to RNS. In severely atrophied muscles, the decremental percentage of Trap and ADM in ALS patients showed a less pronounced decremental response than did the proximal muscles. The lower safety factor of NMJ at the proximal muscle may be an interpretation. Besides, the study indicated that there was a positive linear correlation between the CMAP amplitude and the decremental percentage of Trap and ADM in ALS patients, which supported the decremental mechanisms of immature collateral sprouting and unstable NMJ transmission resulting from axonal degeneration. The Awaji diagnostic criteria indicated that electrophysiological and clinical evidence should be considered equally when judging the lower motor neuron (LMN) involvement in ALS patients. The decremental positive responses in RNS meant an impaired LMN. Moreover, this study showed that the onset of ALS did not affect the RNS decrement responses, which was consistent with previous research. However, some studies have shown that patients with upper limb onset had a higher decremental percentage compared with those with other sites of onset. The underlying reason for these differences is unclear. It was speculated that the limited number of patients with lower limb and bulbar onset as well as the different types of muscles studied may be the underlying interpretations. In any case, more specifically designed research would be necessary to settle this issue. Besides, the patients’ gender, onset age, and disease duration did not affect the RNS decremental percentages.

The decremental responses of ALS patients suggest the instability of NMJ transmission. The underlying mechanism of decremental responses remains controversial. One explanation is that, as the disease progresses, the anterior horn motor neurons of the spinal cord degenerate; then, the muscle fibers dominated by these neurons show denervation, leading to the corresponding NMJ structure changes. The remaining motor neurons around the degenerative neurons dominate the muscle fibers by the collateral sprouts, and new NMJ structures form. Before the new NMJ structures are fully mature, the motor neurons have degenerated and lost. Along with the repeated cycles, these highly immature reinnervations cause an intermittent conduction block in the newly formed nerve endings, eventually leading to a decremental response. Another possible explanation is that the disease arises from distal axons or NMJs and proceeds to the cell body in reverse. This is the “dying back” hypothesis. Fischer et al. performed a good deal of pathological experimentation on the SOD1-G93A mice model and found that NMJ destruction and axon degeneration occurred before motor neurons degenerated. An autopsy on a single ALS patient showed...
denervation and reinnervation changes in muscles, where the motor neurons remained structurally intact (20). The mechanism of “dying back” remains unclear. A possible explanation is energy deficiency resulting from the hypermetabolism and malnutrition of ALS, which could lead to NMJ dysfunction (17).

In conclusion, the decremental positive responses are common in ALS patients, but the pathophysiological mechanisms remain unclear. Advanced research is necessary to discuss whether the decremental percentage > 20% is a diagnostic exclusion criterion for ALS patients. Patients with lower CMAP amplitudes were more prone to show decremental responses, both in the proximal and distal muscles. Besides, the onset age, duration of disease, and onset site of ALS do not affect RNS the decremental responses.

DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the article-supplementary material.

REFERENCES

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. (2011) 377:942–55. doi: 10.1016/S0140-6736(10)61156-7
2. Mulder DW, Lambert EH, Eaton LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology. (1959) 9:627–31. doi: 10.1212/WNL.9.10.627
3. Killian JM, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve. (1994) 17:747–54. doi: 10.1002/mus.880170708
4. Wang FC, De Pasqua V, Gerard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology. (2001) 57:897–9. doi: 10.1212/WNL.57.5.897
5. Iwanami T, Sonoo M, Hatanaka Y, Hokkoku K, Oishi C, Shimizu T. Decremental responses to repetitive nerve stimulation (RNS) in motor neuron disease. Clin Neurophysiol. (2011) 122:2530–6. doi: 10.1016/j.clinph.2011.05.019
6. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revised: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. (2000) 1:293–9. doi: 10.1080/146608200300079536
7. Hu F, Jin J, Kang L, Jia R, Qin X, Liu X, et al. Decremental responses to repetitive nerve stimulation in amyotrophic lateral sclerosis. Eur Neurol. (2018) 80:151–6. doi: 10.1159/000494670
8. Wang Y, Xiao Z, Chu H, Liang J, Wu X, Dong H, et al. Correlations between slow-rate repetitive nerve stimulation and characteristics associated with amyotrophic lateral sclerosis in Chinese patients. J Phys Ther Sci. (2017) 29:737–43. doi: 10.1589/jpts.29.737
9. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. (2008) 119:497–503. doi: 10.1016/j.clinph.2007.09.143
10. Chinese Medical Association. Revised version of experts consensus for standardization for electromyography and clinical application. Chin J Neurol. (2015). 48:950–64. doi: 10.3760/cma.jsnn.1006-7876.2015.11.005
11. Henderson R, Baumann F, Hutchinson N, McCombe P. CMAP decrement in ALS. Muscle Nerve. (2009) 39:555–6. doi: 10.1002/mus.21105
12. Hatanaka Y, Higashihara M, Chiba T, Miyaji Y, Kawamura Y, Sonoo M. Utility of repetitive nerve stimulation test for ALS diagnosis. Clin Neurophysiol. (2017) 128:823–9. doi: 10.1016/j.clinph.2017.02.021

ETHICS STATEMENT

Ethics approval and written informed consent was not required as per local legislation and national guidelines, as repetitive nerve stimulation inspection is considered routine care.

AUTHOR CONTRIBUTIONS

LS drafted the paper. HC was responsible for data collection. ZL provided specialized expertise and critical appraisal of the article for submission.

ACKNOWLEDGMENTS

We are grateful to Drs. Wang Yan, Liu Shuping, and Fu Xiujuan (Department of Neurology, Renmin Hospital, Wuhan University).

13. Mori A, Yamashita S, Nakajima M, Hori H, Tawara A, Matsuo Y, et al. CMAP decrement as a potential diagnostic marker for ALS. Acta Neurol Scand. (2016) 134:49–53. doi: 10.1111/ane.12510
14. Kaires PA. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology. (2002) 58:836–7. doi: 10.1212/WNL.58.5.836
15. Yamashita S, Sakaguchi H, Mori A, Kimura E, Maeda Y, Hirano T, et al. Significant CMAP decrement by repetitive nerve stimulation is more frequent in median than ulnar nerves of patients with amyotrophic lateral sclerosis. Muscle Nerve. (2012) 45:426–8. doi: 10.1002/mus.22301
16. Zheng C, Jin X, Zhu Y, Lu F, Jiang J, Xia X. Repetitive nerve stimulation as a diagnostic aid for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis. Eur Spine J. (2017) 26:1929–36. doi: 10.1007/s00586-017-5060-4
17. Sun XS, Liu WX, Chen ZH, Ling L, Yang F, Wang HF, et al. Repetitive nerve stimulation in amyotrophic lateral sclerosis. Chin Med J. (2018) 131:2146–51. doi: 10.4103/0366-6999.240798
18. Alanzay MH, Hegedus J, White C, Korngut L. Decremental responses in patients with motor neuron disease. Brain Behav. (2017) 7:e846. doi: 10.1002/brb3.846
19. Fu LL, Yin HY, Liu MS, Cui LY. Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. Chin Med J. (2019) 132:542–50. doi: 10.1097/CM9.0000000000001117
20. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. (2004) 185:232–40. doi: 10.1016/j.expneurol.2003.10.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Shang, Chu and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.